Why is the Immutep (ASX:IMM) share price dipping today?

The Immutep (ASX:IMM) share price slipped today after the company posted an update about one of its clinical trials. Here's what we found out.

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is down 1.59% at the time of writing trading at 31 cents a share. This follows this morning's announcement that Immutep is expanding Part B of its cancer treatment clinical trial.

Let's break down what that means and why it could be moving the Immutep share price today.

More patients recruited for expanded trial

Based in Australia, Immutep develops novel immunotherapy treatments for cancer and autoimmune disease.

In today's release, the biotechnology company advised that it had recruited 13 more patients with second-line non-small cell lung cancer (NSCLC) for Stage 1 of the now expanded Part B of its TACTI-002 Phase II trial.

The trial extension follows the recommendation of the data monitoring committee following a preliminary safety and efficacy review. TACTI-002 stands for Two ACTive Immunotherapies. 

Immutep is conducting the trial by treating cancer patients with a combination of its eftilagimod alpha product (efti) and Keytruda®, produced by US pharmaceutical company Merck & Co., Inc (NYSE: MRK).

Efti is in clinical development to treat cancer. Immutep has three additional treatments for cancer and autoimmune disease that also are in clinical development.

Immutep's half-year update

Discussing the company's leading efti product in its latest half-year FY21 results, Immutep advised:

Following the encouraging clinical results announced for efti last year, Immutep is in a very robust financial and operational position.

The company has increasing confidence in efti and accordingly, three new efti trials or trial extensions with up to 386 patients in different cancer indications were announced or started during the half year, in addition to its ongoing clinical trials of the product candidate.

Immutep is also working on scaling up efti manufacturing in preparation for potential commercial manufacturing and additional registration trials in multiple indications.

Immutep share price snapshot

Despite positive progress on its clinical trials, the Immutep share price has taken a 20.3% dive over the past month. Year-to-date, it's fallen 24.1%.

The company presently has a market capitalisation of 217.3 million and there are 648.7 million shares outstanding.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »